EBS - Emergent Biosolutions: Leader In The Public Health Threats Space
Emergent Biosolutions (EBS) is a midcap biopharma with a focus on PHTs or public health threats, whether accidental, naturally occurring or intentional. This includes targeting anthrax, for which the company has an approved product, Zika virus and other pipeline product candidates. The following diagram gives a concise idea about the company’s splendid revenue growth since 2012:
The first chart shows the tremendous revenue growth rate in the last 6 years, almost tripling from $278mn in 2012 to $782mn in 2018. The next figure shows that while only one product, BioThrax, accounted for